Prognostic value of microvascular occlusion MRI quantification in assessment of reperfused myocardial infarction

Abstract

Background

Reperfusion therapy in patients with acute myocardial infarction (AMI) can salvage the myocardium; however, successful restoration of the coronary artery patency is not always associated with adequate perfusion at the level of microvasculature, known as the no-reflow or microvascular occlusion (MVO). The primary objective of our prospective study was to assess, by cardiac magnetic resonance (CMR), the prognostic value of MVO size, and its impact on left ventricular (LV) remodeling in cases of reperfused AMI.

Thirty-three patients with AMI underwent cardiac MRI at 1.5-T scanner within 7 days (baseline) and 3 months (follow-up) after reperfusion. Patients with MVO were included where early gadolinium enhancement (EGE), late gadolinium enhancement (LGE), and cine sequences were acquired. The impact of MVO size on LV ejection fraction (EF%) and LV volumes was quantitively analyzed.

Results

There was a significant inverse correlation between the MVO size % of the LV mass (LVM) and the EF% values measured at follow-up with a P value of 0.000, while a significant positive correlation was encountered between the MVO% of LVM and both indexed end-systolic volume (ESVI) and indexed end-diastolic volume (EDVI) values measured at follow-up with P values of 0.438 and 0.389, respectively. MVO size was found to be a significant factor affecting the patient’s outcome (P = 0.000) where MVO size of > 10% of the total LVM can be a predictor of a worse outcome and reduced EF% at follow-up.

Conclusion

The prognostic value of MVO could be statistically determined with a cut off value to predict a possible good outcome using CMR.

Background

Myocardial infarction (MI) is a leading cause of death and disability worldwide; consequently, its accurate diagnosis is important, since it directs the clinical management and affects the patient’s prognosis [1].

Reperfusion therapy in patients with acute myocardial infarction (AMI) can salvage the myocardium and reduce mortality. However, successful restoration of the coronary artery patency does not always mean that perfusion of the microvasculature is adequately reached leading to what is known as the “no-reflow” or “microvascular occlusion” (MVO) [2].

While multiple different imaging modalities can diagnose the MVO, cardiac magnetic resonance (CMR) has many distinct advantages; it enables precise delineation of both infarct and MVO sizes along with accurate quantification of left ventricular (LV) function and volumes using a single imaging examination with no need for radiation exposure [3].

This study aims to evaluate, by CMR, the impact of MVO size on the regional LV wall characteristics and its local remodeling changes in cases of successfully reperfused acute myocardial infarction.

Methods

Subjects

After obtaining approval from the Institutional Review Board, we conducted a single-center prospective study of AMI patients treated successfully by percutaneous intervention (PCI) reperfusion procedure within 12 h of acute symptoms’ onset. Conventional coronary angiography (in the setting of PCI procedure) detected the culprit lesion at the left anterior descending (LAD) coronary artery in 16 patients (48.5%), right coronary artery (RCA) in 10 patients (30.3%), and left circumflex (LCx) coronary artery in 7 patients (21.2%).

Thirty-three patients were included in our study (28 male, 5 females; mean age: 60.27 ± 8.15 years [range, 40–70 years]) (Table 1). All patients underwent a CMR examination within the first week of the reperfusion procedure and after 3 months in a period between June 2018 and May 2019. They or their guardians had signed the informed consent before proceeding for the examination.

Table 1 Patient characteristics

We excluded patients who underwent reperfusion after 12 h from the onset of symptoms. Also, patients with previous cardiac events (infarction, thrombolysis), any significant valvular diseases, cardiomyopathies, GFR < 30 ml/min/1.73 m^2, or known to have contraindications for the MRI, e.g., an implanted magnetizable device, pacemakers, or claustrophobia, were excluded from our study.

Methods

The MRI study was performed on a 1.5-T scanner (Siemens machine Magnetom Aera, Siemens Medical Systems, Erlangen, Germany). All sequences were ECG- and respiratory-gated with dedicated phased array cardiac coil using a single breath-hold multi-echo technique. The examination time was 30–45 min.

The examination protocol included retrospective ECG-gated cine steady-state free precession (SSFP) sequences during breath-hold in long-axis 2 and 4 chamber views (single slice at mid-LV, TR/TE = 72.75/1.2 ms) and short-axis (SA) stack images covering both ventricles from the base of the heart to the apex for ventricular function assessment (TR/TE = 72.75/1.2 ms). SA-T2W fluid suppression stack images were acquired, using a prospective segmented inversion-recovery gradient-echo pulse sequence, for myocardial edema assessment (TR/TE = 800/52 ms).

T1-weighted SA-early gadolinium enhancement (EGE) stack images, obtained 2–3 min after administration of a gadolinium-based contrast agent (Dotarem, Paris, France, 0.2 mmol/kg), were acquired using a prospective segmented inversion-recovery gradient-echo pulse sequence (TR/TE = 547/3.14 ms), inversion time was set to be 500 ms. Also, T1-weighted SA-late gadolinium enhancement (LGE) stack images, obtained 10 min after injection of the contrast agent, were acquired using also a prospective segmented inversion-recovery gradient-echo pulse sequence for myocardial fibrosis and MVO assessment (TR/TE = 654/1.06 ms). An initial inversion time scout sequence was performed to determine the optimum inversion time.

Left ventricular function was analyzed by dedicated software (Philips intelliSpace portal workstation, version 8.0.) using a previously validated method [4]. End-diastolic volume, end-systolic volume, and ejection fraction were all normalized to body surface area using the Mostellar formula [5, 6].

The left ventricular myocardial infarct and MVO volume quantification were performed by manually defining areas of enhancement on all the short-axis slices from the base to the apex using Segment CMR software, version 2.0, Mediviso.

Statistical analysis

For all volumetric measurements, the means and SD are quoted, with ranges from the 95% confidence intervals. Data were analyzed by SPSS statistical analysis program (SPSS version 23). It was summarized using descriptive statistics: number and percentage for qualitative values and mean and standard deviation, and median and interquartile range for quantitative variables. The paired-sample t test was used to compare differences in global LV parameters between baseline and follow-up examinations and the independent-sample t test was used to compare mean values between subgroups. All statistical tests were two-tailed and a P value of less than 0.05 was considered to indicate a significant difference.

Results

Forty patients met the inclusion criteria. Four patients were excluded due to claustrophobia, 2 patients refused to follow-up, and 1 patient died before completing his follow-up due to a non-cardiac cause. So 33 patients could complete the baseline and follow-up scans and were included in our statistical analysis. No cardiac deaths or major cardiac adverse events were noticed during the 3-months follow-up period.

Included patients (n = 33) were screened twice, within 1 week of the reperfusion procedure as a baseline scan and after 3 months as a follow-up scan, the infarct size % of the left ventricular mass (LVM) and MVO size % of the LVM were calculated in the baseline scan. The median MVO size % of LVM was 10 (1–43) and the mean scar size % of LVM was 41.00 ± 15.42 (19–74). All patients showed complete resolution of the MVO at the follow-up scan.

The LV EF%, LV end-diastolic volume index (EDVI), LV end-systolic volume index (ESVI), and LV stroke volume index (SVI) values were calculated in the baseline and follow-up scans and were compared to each other. Compared to the baseline scan, there was a significant increase in the follow-up scan values as regards the mean EDVI (P = 0.000), mean ESVI (P = 0.005), and mean SVI (P = 0.007) using a paired t test; while a significant decrease in the mean EF% values was encountered at follow-up (P = 0.001) (Table 2, Figs. 1 and 2).

Table 2 Paired comparison of LVEF% and LV volumes at 1st (baseline) and 2nd (follow-up) visits in all cases (n = 33)

Fig. 1

A chart showing LV EF% and SVI measured at 1st (baseline) and 2nd (follow-up) visits

Fig. 2

A chart showing LV EDVI and ESVI measured at 1st (baseline) and 2nd (follow-up) visits

There was a significant positive correlation between the size of the MVO and the infarct measured at the baseline scan (P value = 0.000) and a significant inverse correlation between the MVO size % of the LVM and the EF% values measured at the follow-up scans (P value of 0.000), while a significant positive correlation was encountered between the MVO% of LVM and both ESVI and EDVI values measured in the follow-up scans with P values of 0.011, 0.025, respectively (Table 3; Figs. 3, 4, and 5).

Table 3 Correlation between MVO size % and baseline scar size together with LV volumes measured at 2nd visit (follow-up) and its significance

Fig. 3

A scatter plot matrix showing a significant inverse correlation between MVO size % and LVEF% measured at the 2nd visit (follow-up)

Fig. 4

A scatter plot matrix showing a significant positive correlation between MVO size % and LV EDVI measured at the 2nd visit (follow-up)

Fig. 5

A scatter plot matrix showing a significant a positive correlation between MVO size % and LV ESVI measured at the 2nd visit (follow-up)

Based on the follow-up EF% values, our patients were divided into 2 groups; a good-outcome group (n = 18, 54.5), representing good prognosis, where the EF% was stationary or improved in comparison to those measured in the baseline scan (Figs. 6 and 7), and a poor-outcome group (n = 15, 45.5%), representing bad prognosis, where the EF% was reduced (Figs. 8 and 9). The MVO size % of the LVM was found to be significantly affecting the outcome with P = 0.000 using an independent t test (Fig. 10).

Fig. 6

a Cardiac MR performed for a patient 4 days post-primary percutaneous coronary intervention. Short-axis EGE sequence at mid-ventricular level shows a sub-endocardial inferior and infero-septal left ventricular wall low signal corresponding to microvascular obstruction. b Corresponding short-axis LGE sequence showing transmural inferior and infero-septal left ventricular wall hyperenhancement/infarct with central low signal microvascular obstruction. Culprit lesion was detected at RCA. c Corresponding short-axis T1W LGE sequence with post-processing of the LV scar (green) and MVO (yellow) revealing an MVO size = 9% and infarct size = 27% of the total left ventricular mass (LVM). Follow-up short-axis LGE sequence, after 3 months, showing transmural inferior and sub-endocardial infero-septal left ventricular wall fibrosis scar with complete resolution of the MVO

Fig. 7

Represent LV functional post-processing for the SSFP cine images taken for the previous patient; the endocardial (red) and epicardial borders (green) are manually delineated to obtain LV volumes, mass, and EF. a–c Basal, mid, and apical cuts at the baseline scan, calculated EF% was 56%. d-f Basal, mid, and apical cuts for the same patient acquired at the follow-up scan, calculated EF% was 54%

Fig. 8

a Cardiac MR performed for a patient 5 days post-primary percutaneous coronary intervention. Short-axis EGE sequence showing anterior and entire septal low signal corresponding to a large region of microvascular obstruction. b Corresponding short-axis LGE sequence showing full-thickness hyperenhancement/infarct involving anterior, entire septal, and inferior left ventricular wall. The septal low signal within the infarct corresponds to a large region of microvascular obstruction. Culprit lesion was detected at LAD artery. c: Corresponding Short-axis LGE sequence with post-processing of the LV scar (green) and MVO (yellow) revealing an MVO size = 43% and scar size = 93% of the total left ventricular mass (LVM). d Follow-up short-axis LGE sequence, after 3 months, transmural anterior, transmural septal, and sub-endocardial inferior left ventricular wall fibrosis scar with complete resolution of the MVO

Fig. 9

Represent LV functional post-processing for the SSFP cine images taken for the previous patient; the endocardial (red) and epicardial borders (green) are manually delineated to obtain LV volumes, mass, and EF. a–c Basal, mid, and apical cuts at the baseline scan, calculated EF% was 35%. d–f Basal, mid, and apical cuts for the same patient acquired at the follow-up scan, calculated EF% was 28%

Fig. 10

A pie chart showing the percentage of good- and poor-outcome patients

Finally, a ROC curve for the predictors of a good outcome was statistically generated revealing that MVO size of < 10% of LVM is the cut off value for possible good prognosis with 94.44% sensitivity and 100% specificity (Fig. 11).

Fig. 11

ROC curve for the predictors of a good outcome

Discussion

MVO was first described in the 1970s [7]. It is usually encountered in up to 30% of the patients, as a reperfusion injury, following prolonged myocardial ischemia; the perfusion of the ischemic myocardium at the microvascular level is either unrestored or incompletely restored [2].

The pathophysiological mechanisms resulting in MVO development remain ill-defined; previous studies suggested multiple factors that can explain the mechanism of its formation [7, 8]. Swollen endothelial cells with intravascular luminal protrusions together with swollen myocytes occlude the capillaries. Also, the activation of neutrophils together with the platelets’ deposition of fibrin contributes to microvascular damage. In addition to these factors, microvascular capillaries embolization with the atherosclerotic debris following the PCI procedure play an important role in microvascular capillaries’ obstruction [2].

MVO can be demonstrated via multiple imaging modalities; CMR is a valid tool that can accurately diagnose and quantify MVO. The major benefits of using CMR include the absence of radiation exposure, safety, being a non-invasive method, and a reproducible examination [9].

Studies showed that the extent of MVO, seen on CMR, shows a close correlation with the anatomical extent of MVO in both animals and humans. MVO size increases over the first 2 days following the PCI procedure and starts to reduce in size 2 to 7 days afterward [10]; most of the patients demonstrate complete resolution of MVO when screened 4 to 6 weeks post-PCI [3]. Consequently, in this study, we screened the patients within 1 week and 3 months of the post-reperfusion procedure. More important, MVO assessed on LGE imaging seems to have superior prognostic value to that assessed at early imaging besides it has a good spatial resolution [11]. Thus, in the present study, MVO was quantitively analyzed at the LGE images. It represents a central “dark zone” within the hyper-enhanced region on gadolinium-enhanced MRI sequences.

Though conflicting data still exist concerning the MVO presence and regional function recovery [11], yet multiple studies have shown that MVO has a significant adverse prognostic impact on the LV remodeling [8, 12] and that patients with MVO demonstrate greater left ventricular end-diastolic and end-systolic volumes at follow-up visits [10, 12,13,14]. We managed to confirm these findings in our study where we detected a significant increase in the follow-up scan values as regards the mean EDVI, the mean ESVI, and the mean SVI. Besides, we detected a significant inverse correlation between the MVO size % of the LVM and the follow-up EF% values together with a significant positive correlation between the MVO size % of LVM and both ESVI and EDVI values measured in the follow-up scans.

The regional systolic function can be an independent predictor for patient outcome after MI [15] So, we divided the patients of this study into a good-outcome group (n = 18, 54.5%), representing possible good prognosis, where the follow-up EF% was stationary or improved in comparison to those measured in the baseline scan, and a poor-outcome group (n = 15, 45.5%), where the follow-up EF% was reduced; the MVO size in this study was found to be a significant factor affecting the type of outcome. More important, an MVO size of < 10% of LVM was found to be statistically the cut off value for a possible good outcome with high sensitivity (94.44%) and specificity (100%). Thus, the prognostic value for the MVO size could be suggested in our study.

Several limitations of this study should be mentioned. The studied population is relatively small in size with no control group for comparison. We only used the EDVI, EDSVI, SVI, and EF% values as determinants for LV remodeling and the patients’ prognosis. Also, we did not perform T2 or T2* MR sequences to detect intra-myocardial hemorrhage, so its effect could not be assessed.

Conclusion

MVO size of < 10% of the LVM can be considered the cut off value for a possible good outcome. Thus, the prognostic value of MVO’s size can be statistically determined using CMR. More studies are required to study local LV remodeling after AMI with a larger sample size and with broader spectrum; for example, comparing patient groups undergoing different reperfusion therapies, or exploring its evolution in multiple time points.